NEW YORK, Nov. 4 (GenomeWeb News) - Invitrogen said today that it has acquired privately held RNAi technology firm Sequitur of Natick, Mass.
Financial terms of the acquisition were not disclosed.
Claude Benchimol, Invitrogen's senior vice president of R&D, said that the acquisition will add to Invitrogen's "growing RNAi platform." Benchimol said that Sequitur's Stealth RNAi technology, which uses proprietary chemically modified synthetic RNAi molecules, performs "better than conventional short-interfering RNA" and can be combined with Invitrogen's Lipofectamine transfection reagents.
Invitrogen's RNAi product line, marketed under the Block-it trade name, includes transfection agents, vectors, oligonucleotides, and other products.
"With its patent position, we believe Sequitur Inc.'s Stealth technology will prevail as the standard method for how researchers perform RNAi," said Invitrogen CEO Gregory Lucier.